A detailed history of High Tower Advisors, LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 15,333 shares of CRDF stock, worth $37,719. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,333
Previous 16,035 4.38%
Holding current value
$37,719
Previous $35,000 14.29%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.05 - $2.77 $1,439 - $1,944
-702 Reduced 4.38%
15,333 $40,000
Q2 2024

Aug 13, 2024

SELL
$2.22 - $5.89 $4,362 - $11,573
-1,965 Reduced 10.92%
16,035 $35,000
Q1 2024

May 06, 2024

BUY
$1.46 - $5.91 $3,893 - $15,761
2,667 Added 17.39%
18,000 $96,000
Q3 2022

Nov 09, 2022

BUY
$1.54 - $3.21 $23,612 - $49,218
15,333 New
15,333 $23,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $107M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.